IL17A and rheumatoid arthritis: The IL-23/IL-17 axis has been implicated in driving intrinsic inflammatory activity and triggering the clinical onset of rheumatoid arthritis, primarily in animal models, suggesting that early intervention in the pre–rheumatoid arthritis phase could potentially lead to clinical improvement (111, 119).